Lessons From the SONIA Trial on Timing of CDK4/6 Inhibitors in Advanced Breast Cancer-The Sooner, the Better?
APA
Valenza C, Burstein HJ (2026). Lessons From the SONIA Trial on Timing of CDK4/6 Inhibitors in Advanced Breast Cancer-The Sooner, the Better?. JAMA oncology, 12(4), 353-355. https://doi.org/10.1001/jamaoncol.2025.6345
MLA
Valenza C, et al.. "Lessons From the SONIA Trial on Timing of CDK4/6 Inhibitors in Advanced Breast Cancer-The Sooner, the Better?." JAMA oncology, vol. 12, no. 4, 2026, pp. 353-355.
PMID
41712236
같은 제1저자의 인용 많은 논문 (4)
- Bridging the Gap: Advancing First-Line Therapy for Patients With Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
- Optimizing adjuvant endocrine therapy in premenopausal patients with HER2-positive, hormone receptor-positive breast cancer.
- Inadequate ovarian function suppression and endocrine therapy manipulations in premenopausal patients with early breast cancer on adjuvant LHRH agonist and aromatase inhibitor: a cohort study.
- Extended Endocrine Therapy Following 5 Years of Adjuvant Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal Patients With Node-Positive, Hormone Receptor-Positive Breast Cancer: A Cohort Study.